Bunzl Plc shares advanced after a mid-year trading bulletin on Monday, June 22, which included a firmer revenue forecast for the full year 2026 and a small acquisition in Australia. The stock rose 1.7% to 2506p following the release.
In the update the FTSE 100 distributor said it now expects first-half revenue to increase by approximately 4% at constant exchange rates. That figure includes underlying revenue growth of about 3%, a material improvement compared with the company's earlier guidance that had described growth as "moderate." Management attributed the upgraded top-line outlook to product-cost inflation arising from geopolitical developments in the second quarter and to faster volume trends, with North America cited as a particular source of momentum.
The company also disclosed the acquisition of Scientifix Group, an Australian distributor serving the Life Sciences and Biotechnology sector. Bunzl said the deal is expected to add roughly 1% to revenue growth, marking a targeted bolt-on that extends the group's geographical exposure and sector footprint.
Crucially for investors, Bunzl signalled a change in profit expectations. Management now projects adjusted operating profit to increase year-on-year, accompanied by a slight margin improvement. That represents a reversal from the earlier guidance that margins would be "slightly down," language that had previously weighed on market sentiment.
CEO Frank van Zanten was quoted emphasising the strong operational progress in Bunzl's North American Distribution business and reiterating that 2026 should serve as a base for longer-term profit growth.
The share movement came against a tougher market backdrop. FTSE 100 futures opened sharply lower during the session, reversing recent gains after a steep selloff in U.S. technology stocks left the Nasdaq down 1.3%. Bunzl's ability to trade higher in this environment underlines how the company-specific upgrades outweighed broader macroeconomic headwinds for investors in the stock.
On a technical basis, the shares remain well inside their 52-week trading range of 1982p to 2632p, which market commentary suggested leaves room for recovery toward earlier highs should the upgraded outlook be sustained.
Contextual takeaways
- Above-expectations H1 trading metrics, a revised profit outlook, and a small Australian acquisition combined to provide three clear catalysts for the stock.
- Revenue drivers cited by management included product-cost inflation linked to geopolitical developments and accelerating volumes, with North America singled out for strong operational performance.
- The Scientifix deal adds exposure to the Life Sciences and Biotechnology distribution market and is expected to contribute about 1% to revenue growth.